Background: There are few studies to compare antibody response against anti-spike (S) and anti- nucleoprotein (N) SARS-CoV-2.
Objective: The aim of this study was to evaluate the IgG antibody production against S and N antigens of the virus and their correlation with the time and severity of the disease.
Methods: The IgG antibodies against S and N antigens of SARS-CoV-2 in serum specimens of 72 symptomatic patients who tested real-time reverse transcription polymerase chain reaction positive for SARS-CoV-2 were detected using the ELISA technique. Different antibody response was compared and the correlation with the time from disease onset and the severity was evaluated.
Results: Forty-eight of 72 (67%) patients tested positive for anti-SARS-CoV-2 antibodies, while 24 (33%) did not have detectable antibodies. Comparison of antibody levels for N and S antibodies showed that they correlate with each other well (r= 0.81; P< 0.001). However, sensitivity of anti-S SARS-CoV-2 IgG and anti-N SARS-CoV-2 IgG was 30% and 60%, during the first 7 days after symptom onset (r= 0.53; P= 0.111), but increased to 73% and 68% at more than 1-week post symptom onset (r= 0.89, P= 0.111), respectively. Cases with positive IgG response showed a decreased CD8+ T cells percentage compared to the negative IgG groups (26 ± 14 vs. 58 ± 32, p= 0.066 in anti-N IgG group and 28 ± 15 vs. 60 ± 45, p= 0.004 in anti-S IgG group, respectively).
Conclusion: Nearly one-third of the confirmed COVID-19 patients had negative serology results. Lower percent positivity at early time points after symptom onset (less than 1 week) was seen using anti-S SARS-COV-2 IgG kit compare to the anti-N SARS-CoV-2 IgG; therefore, clinicians should interpret negative serology results of especially anti-S SARS-CoV-2 IgG with caution.
{"title":"Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens.","authors":"Mitra Rezaei, Mohammadhadi Sadeghi, Alireza Korourian, Payam Tabarsi, Mihan Porabdollah, Elham Askari, Esmaeil Mortaz, Shima Mahmoudi, Majid Marjani, Ali Akbar Velayati","doi":"10.3233/HAB-210440","DOIUrl":"https://doi.org/10.3233/HAB-210440","url":null,"abstract":"<p><strong>Background: </strong>There are few studies to compare antibody response against anti-spike (S) and anti- nucleoprotein (N) SARS-CoV-2.</p><p><strong>Objective: </strong>The aim of this study was to evaluate the IgG antibody production against S and N antigens of the virus and their correlation with the time and severity of the disease.</p><p><strong>Methods: </strong>The IgG antibodies against S and N antigens of SARS-CoV-2 in serum specimens of 72 symptomatic patients who tested real-time reverse transcription polymerase chain reaction positive for SARS-CoV-2 were detected using the ELISA technique. Different antibody response was compared and the correlation with the time from disease onset and the severity was evaluated.</p><p><strong>Results: </strong>Forty-eight of 72 (67%) patients tested positive for anti-SARS-CoV-2 antibodies, while 24 (33%) did not have detectable antibodies. Comparison of antibody levels for N and S antibodies showed that they correlate with each other well (r= 0.81; P< 0.001). However, sensitivity of anti-S SARS-CoV-2 IgG and anti-N SARS-CoV-2 IgG was 30% and 60%, during the first 7 days after symptom onset (r= 0.53; P= 0.111), but increased to 73% and 68% at more than 1-week post symptom onset (r= 0.89, P= 0.111), respectively. Cases with positive IgG response showed a decreased CD8+ T cells percentage compared to the negative IgG groups (26 ± 14 vs. 58 ± 32, p= 0.066 in anti-N IgG group and 28 ± 15 vs. 60 ± 45, p= 0.004 in anti-S IgG group, respectively).</p><p><strong>Conclusion: </strong>Nearly one-third of the confirmed COVID-19 patients had negative serology results. Lower percent positivity at early time points after symptom onset (less than 1 week) was seen using anti-S SARS-COV-2 IgG kit compare to the anti-N SARS-CoV-2 IgG; therefore, clinicians should interpret negative serology results of especially anti-S SARS-CoV-2 IgG with caution.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"109-113"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-210440","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25481445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The Novel Coronavirus Disease 2019 (COVID-19) has proved to be one of the most burdensome respiratory disease outbreaks ever. Moreover, the public health emergency of the COVID-19 outbreak has been seen by the World Health Organization (WHO) as global health concern since March 2020 and there has been a significantly increased morbidity and mortality in the community worldwide. The objective of this review is to describe and review the global public health significances and community and healthcare perception of features, treatments, prevention and control methods to slow the transmission of the outbreak.
Methods: For this review, the literature has been searched by following online databases, including medRxiv, pubmed, medline and Google scholar databases. The key search terms 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus' and 'Pneumonia' were used to search the literature. Scientific papers published online by the Center for Disease Control (CDC) and the WHO from 01 January to 06 May 2020 in the English language were included for analysis.
Results: The results of this review indicated that COVID-19 is a serious global public health problem. It affects immune compromised individuals living with chronic diseases, the elderly and pregnant women more severely. The disease spread rapidly from one country to countries worldwide. In all, 212 countries highlighted the weakened state of essential public health and emergency services. The researchers addressed the lack of perception in communities, including health professionals, with regard to COVID-19. Healthcare settings were analyzed in terms of the pandemic nature of the virus, onset and the overall characteristics of disease outbreak. Microbiogists were also used to assess the daily cumulative index of COVID-19. With regard to treatment, chloroquine phosphate and herbal medicines were shown to be promising as supportive treatments to slow COVID-19 transmission, coupled with isolation and quarantine techniques.
Conclusion: The review indicates that COVID-19 has a high global public health significance due to its high morbidity and mortality rates. Still, there was no specific or effective vaccine or treatment, moreover, the community, including health professionals, have a low perception as regards COVID-19, even though different prevention and control methods have been conducted. Thus, there is a need for awareness creation, alongside further research applied to finding effective vaccine and treatments.
{"title":"Global public health significances, healthcare perceptions of communities, treatments, prevention and control methods of COVID-19.","authors":"Addis Adera Gebru, Tadesse Birhanu, Eshetu Wendimu, Agumas Fentahun Ayalew, Selamawit Mulat, Hussen Zakir Abasimel, Ali Kazemi, Bosenu Abera Tadesse, Beniam Adera Gebru, Berhanu Senbeta Deriba, Nigus Shimelis Zeleke, Abebe Gule Girma, Bulgantsetseg Munkhbat, Qamar Kassim Yusuf, Amana Ogeto Luke, Dejene Hailu","doi":"10.3233/HAB-200422","DOIUrl":"https://doi.org/10.3233/HAB-200422","url":null,"abstract":"<p><strong>Background: </strong>The Novel Coronavirus Disease 2019 (COVID-19) has proved to be one of the most burdensome respiratory disease outbreaks ever. Moreover, the public health emergency of the COVID-19 outbreak has been seen by the World Health Organization (WHO) as global health concern since March 2020 and there has been a significantly increased morbidity and mortality in the community worldwide. The objective of this review is to describe and review the global public health significances and community and healthcare perception of features, treatments, prevention and control methods to slow the transmission of the outbreak.</p><p><strong>Methods: </strong>For this review, the literature has been searched by following online databases, including medRxiv, pubmed, medline and Google scholar databases. The key search terms 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus' and 'Pneumonia' were used to search the literature. Scientific papers published online by the Center for Disease Control (CDC) and the WHO from 01 January to 06 May 2020 in the English language were included for analysis.</p><p><strong>Results: </strong>The results of this review indicated that COVID-19 is a serious global public health problem. It affects immune compromised individuals living with chronic diseases, the elderly and pregnant women more severely. The disease spread rapidly from one country to countries worldwide. In all, 212 countries highlighted the weakened state of essential public health and emergency services. The researchers addressed the lack of perception in communities, including health professionals, with regard to COVID-19. Healthcare settings were analyzed in terms of the pandemic nature of the virus, onset and the overall characteristics of disease outbreak. Microbiogists were also used to assess the daily cumulative index of COVID-19. With regard to treatment, chloroquine phosphate and herbal medicines were shown to be promising as supportive treatments to slow COVID-19 transmission, coupled with isolation and quarantine techniques.</p><p><strong>Conclusion: </strong>The review indicates that COVID-19 has a high global public health significance due to its high morbidity and mortality rates. Still, there was no specific or effective vaccine or treatment, moreover, the community, including health professionals, have a low perception as regards COVID-19, even though different prevention and control methods have been conducted. Thus, there is a need for awareness creation, alongside further research applied to finding effective vaccine and treatments.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"129-137"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200422","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38327229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The novel Coronavirus Disease 2019 (COVID-19) is the major public health burden in the world. The morbidity and mortality of the global community due to this disease is dramatically increasing from time to time.
Objective: This situational analysis is aimed to analyse prevalence and incidence of COVID-19 and to provide clear information about this disease for the scientific community, stakeholders, healthcare practitioners and decision-makers.
Methods: The literatures were identified by searching the key relevant and officially known online databases: medRxiv, Google scholar and PubMed. The online databases contain archives of most English biomedical journals and scientific papers published online from 31 December to 3 April 2020 were included. After the literature search, articles were screened independently by two reviewers for eligibility.
Results: The world continents have confirmed a total of 1,202,320 confirmed COVID-19 cases: (51.2%) in Europe, (27.7%) in North America, (17.9%) in Asia, (1.96%) in South America and at less number of confirmed COVID-19 cases in Africa and Australia which was accounted 0.8% and 0.5%, respectively. However, this review showed that there was a significant increase in the confirmed COVID-19 cases by 109,555 in Asia, 8,658 in Africa, 332,866 in North America, 20,269 in South America, 568,894 in Europe, 5,051 in Australia and 1,045,403 in the whole world, with the exception of Antartica, during the review period. The overall results showed that there were 1,098,762 cases and 59,172 deaths recorded during the review period. The result zero number of deaths with COVID-19 was observed in 66 countries.
Conclusion: The review concluded that COVID-19; SARS-CoV-2 is the major public health burden in the world, the morbidity and mortality of global community is dramatically increasing from time to time. Strong collaboration among all sectors and the design of effective prevention and control strategies which include staying home, social/physical distancing, quarantine, testing of suspected patients, isolation and managing of the confirmed cases. Therefore, all countries should implement five major COVID-19 prevention and control programmes as soon as possible at community level.
{"title":"Global burden of COVID-19: Situational analyis and review.","authors":"Addis Adera Gebru, Tadesse Birhanu, Eshetu Wendimu, Agumas Fentahun Ayalew, Selamawit Mulat, Hussen Zakir Abasimel, Ali Kazemi, Bosenu Abera Tadesse, Beniam Adera Gebru, Berhanu Senbeta Deriba, Nigus Shimelis Zeleke, Abebe Gule Girma, Bulgantsetseg Munkhbat, Qamar Kassim Yusuf, Amana Ogeto Luke, Dejene Hailu","doi":"10.3233/HAB-200420","DOIUrl":"https://doi.org/10.3233/HAB-200420","url":null,"abstract":"<p><strong>Background: </strong>The novel Coronavirus Disease 2019 (COVID-19) is the major public health burden in the world. The morbidity and mortality of the global community due to this disease is dramatically increasing from time to time.</p><p><strong>Objective: </strong>This situational analysis is aimed to analyse prevalence and incidence of COVID-19 and to provide clear information about this disease for the scientific community, stakeholders, healthcare practitioners and decision-makers.</p><p><strong>Methods: </strong>The literatures were identified by searching the key relevant and officially known online databases: medRxiv, Google scholar and PubMed. The online databases contain archives of most English biomedical journals and scientific papers published online from 31 December to 3 April 2020 were included. After the literature search, articles were screened independently by two reviewers for eligibility.</p><p><strong>Results: </strong>The world continents have confirmed a total of 1,202,320 confirmed COVID-19 cases: (51.2%) in Europe, (27.7%) in North America, (17.9%) in Asia, (1.96%) in South America and at less number of confirmed COVID-19 cases in Africa and Australia which was accounted 0.8% and 0.5%, respectively. However, this review showed that there was a significant increase in the confirmed COVID-19 cases by 109,555 in Asia, 8,658 in Africa, 332,866 in North America, 20,269 in South America, 568,894 in Europe, 5,051 in Australia and 1,045,403 in the whole world, with the exception of Antartica, during the review period. The overall results showed that there were 1,098,762 cases and 59,172 deaths recorded during the review period. The result zero number of deaths with COVID-19 was observed in 66 countries.</p><p><strong>Conclusion: </strong>The review concluded that COVID-19; SARS-CoV-2 is the major public health burden in the world, the morbidity and mortality of global community is dramatically increasing from time to time. Strong collaboration among all sectors and the design of effective prevention and control strategies which include staying home, social/physical distancing, quarantine, testing of suspected patients, isolation and managing of the confirmed cases. Therefore, all countries should implement five major COVID-19 prevention and control programmes as soon as possible at community level.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"139-148"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200420","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38269910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hossein Ali Khazaei, Majid Naderi, Ghasem Miri Aliabad, Seyed Mohammad Nasiraldin Tabatabaei, Ali Alidadi, Nezar Ali Moulaei, Mohammad Safdari, Hedayatollah Nahvi, Nader Cohan, Javid Dehghan, Ahmad Mehraban, Arman Jalili, Amin Khazaei, Ehsan Khazaei, Bahman Khazaei, Behnam Khazaei, Nima Rezaei, Morteza Salarzaie, Gholamreza Soleimani
Background and objectives: The aim of this study was to investigate the T helper (Th) to T cytotoxic (Tc) ratio in children suffering from type A hemophilia disease and to evaluate the correlation of this ratio with disease severity.
Material and method: Two mls of EDTA anti coagulated whole blood was collected. Immunophenotyping of lymphocytes count was carried out by FACS analysis using a double CD4 and CD8 kit. The mean ± SD of absolute numbers of CD4 and CD8 lymphocytes/ml was calculated and the ratio of CD4/CD8 was evaluated by statistical method.
Results: Among 80 type A hemophilia patients, 66 (82.5%) were male. The mean age was 15 ± 3.51 years. 12 (15%) of them were suffering from mild disease and 68 (85%) had sever disease. The CD4 /CD8 ratio was obtained between 0.45 and 1.44 with mean1.79 ± 0.78. The correlation between this ration and disease severity was 0.019.
Conclusion: The results showed that CD4/CD8 ratio has correlation with disease severity in type A hemophilia patients, however there was no association between this ratio and gender.
{"title":"The effect of T helper (Th)/T cytotoxic (Tc) ratio on disease severity in type A hemophilia patients.","authors":"Hossein Ali Khazaei, Majid Naderi, Ghasem Miri Aliabad, Seyed Mohammad Nasiraldin Tabatabaei, Ali Alidadi, Nezar Ali Moulaei, Mohammad Safdari, Hedayatollah Nahvi, Nader Cohan, Javid Dehghan, Ahmad Mehraban, Arman Jalili, Amin Khazaei, Ehsan Khazaei, Bahman Khazaei, Behnam Khazaei, Nima Rezaei, Morteza Salarzaie, Gholamreza Soleimani","doi":"10.3233/HAB-200434","DOIUrl":"https://doi.org/10.3233/HAB-200434","url":null,"abstract":"<p><strong>Background and objectives: </strong>The aim of this study was to investigate the T helper (Th) to T cytotoxic (Tc) ratio in children suffering from type A hemophilia disease and to evaluate the correlation of this ratio with disease severity.</p><p><strong>Material and method: </strong>Two mls of EDTA anti coagulated whole blood was collected. Immunophenotyping of lymphocytes count was carried out by FACS analysis using a double CD4 and CD8 kit. The mean ± SD of absolute numbers of CD4 and CD8 lymphocytes/ml was calculated and the ratio of CD4/CD8 was evaluated by statistical method.</p><p><strong>Results: </strong>Among 80 type A hemophilia patients, 66 (82.5%) were male. The mean age was 15 ± 3.51 years. 12 (15%) of them were suffering from mild disease and 68 (85%) had sever disease. The CD4 /CD8 ratio was obtained between 0.45 and 1.44 with mean1.79 ± 0.78. The correlation between this ration and disease severity was 0.019.</p><p><strong>Conclusion: </strong>The results showed that CD4/CD8 ratio has correlation with disease severity in type A hemophilia patients, however there was no association between this ratio and gender.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 1","pages":"95-99"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200434","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38764909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michela Flego, Gianni Colotti, Alessandro Ascione, Maria Luisa Dupuis, Eleonora Petrucci, Roberta Riccioni, Mauro Andreotti, Carla Raggi, Alessandra Boe, Stefano Barca, Mara Gellini, Stefano Vella, Alessandra Mallano
Background: The NCAM or CD56 antigen is a cell surface glycoprotein belonging to the immunoglobulin super-family involved in cell-cell and cell-matrix adhesion. NCAM is also over-expressed in many tumour types and is considered a tumour associated antigen, even if its role and biological mechanisms implicated in tumour progression and metastasis have not yet to be elucidated. In particular, it is quite well documented the role of the interaction between the NCAM protein and the fibroblast growth factor receptor-1 in metastasis and invasion, especially in the ovarian cancer progression.
Objective: Here we describe the isolation and preliminary characterization of a novel human anti-NCAM single chain Fragment variable antibody able to specifically bind NCAM-expressing cells, including epithelial ovarian cancer cells.
Methods: The antibody was isolate by phage display selection and was characterized by ELISA, FACS analysis and SPR experiments. Interference in EOC migration was analyzed by scratch test.
Results: It binds a partially linear epitope lying in the membrane proximal region of two fibronectin-like domains with a dissociation constant of 3.43 × 10-8 M. Interestingly, it was shown to interfere with the NCAM-FGFR1 binding and to partially decrease migration of EOC cells.
Conclusions: According to our knowledge, this is the first completely human antibody able to interfere with this newly individuated cancer mechanism.
{"title":"Isolation and preliminary characterization of a human 'phage display'-derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding.","authors":"Michela Flego, Gianni Colotti, Alessandro Ascione, Maria Luisa Dupuis, Eleonora Petrucci, Roberta Riccioni, Mauro Andreotti, Carla Raggi, Alessandra Boe, Stefano Barca, Mara Gellini, Stefano Vella, Alessandra Mallano","doi":"10.3233/HAB-200431","DOIUrl":"https://doi.org/10.3233/HAB-200431","url":null,"abstract":"<p><strong>Background: </strong>The NCAM or CD56 antigen is a cell surface glycoprotein belonging to the immunoglobulin super-family involved in cell-cell and cell-matrix adhesion. NCAM is also over-expressed in many tumour types and is considered a tumour associated antigen, even if its role and biological mechanisms implicated in tumour progression and metastasis have not yet to be elucidated. In particular, it is quite well documented the role of the interaction between the NCAM protein and the fibroblast growth factor receptor-1 in metastasis and invasion, especially in the ovarian cancer progression.</p><p><strong>Objective: </strong>Here we describe the isolation and preliminary characterization of a novel human anti-NCAM single chain Fragment variable antibody able to specifically bind NCAM-expressing cells, including epithelial ovarian cancer cells.</p><p><strong>Methods: </strong>The antibody was isolate by phage display selection and was characterized by ELISA, FACS analysis and SPR experiments. Interference in EOC migration was analyzed by scratch test.</p><p><strong>Results: </strong>It binds a partially linear epitope lying in the membrane proximal region of two fibronectin-like domains with a dissociation constant of 3.43 × 10-8 M. Interestingly, it was shown to interfere with the NCAM-FGFR1 binding and to partially decrease migration of EOC cells.</p><p><strong>Conclusions: </strong>According to our knowledge, this is the first completely human antibody able to interfere with this newly individuated cancer mechanism.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 1","pages":"63-84"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200431","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38584014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Signal Transducer and Activator of Transcription (STAT) pathway is functionally located downstream of Janus kinases proteins and can integrate signals from diverse pathways, thus regulating several aspects of immune responses. Although contribution of STAT proteins in the pathogenesis of several inflammatory conditions has been confirmed, their role in the development of periodontitis has been less appraised. Thus, we assessed levels of STAT transcripts in the periodontal tissues and circulation of affected individuals compared with the corresponding controls. Expression of STAT1 was remarkably lower in tissues samples of patients compared with control tissues (Ratio of mean expression (RME) = 0.15, SE = 0.99, P value = 0.01). Expression of STAT3 was lower in total periodontitis tissues compared with total control tissues (RME = 0.20, SE = 0.95, P value = 0.02). Expression of STAT6 was higher in total periodontitis tissues compared with total control tissues (RME = 0.5.38, SE = 0.74, P value < 0.001). Expressions of other STAT genes were statistically similar in tissues obtained from cases and controls. Moreover, blood levels of all STAT genes were statistically similar between patients and controls. Correlation analysis demonstrated significant correlations between tissues levels of individual STAT genes as well as between their blood levels. However, tissue and blood levels of each STAT gene were not correlated. The current investigation potentiates the role of certain STAT genes in the development of this immune-related condition and warrants functional assays to clarify the mechanism.
信号换能器和转录激活器(Signal Transducer and Activator of Transcription, STAT)通路在功能上位于Janus激酶蛋白的下游,可以整合多种通路的信号,从而调节免疫应答的多个方面。虽然STAT蛋白在几种炎症的发病机制中的作用已经得到证实,但它们在牙周炎发展中的作用却很少得到评价。因此,我们评估了受影响个体的牙周组织和循环中STAT转录本的水平,并与相应的对照进行了比较。STAT1在患者组织样本中的表达明显低于对照组(RME = 0.15, SE = 0.99, P值= 0.01)。STAT3在牙周炎组织中的表达低于对照组(RME = 0.20, SE = 0.95, P值= 0.02)。STAT6在牙周炎总组织中的表达高于对照组(RME = 0.5.38, SE = 0.74, P值< 0.001)。其他STAT基因在病例和对照组织中的表达在统计学上相似。此外,所有STAT基因的血液水平在患者和对照组之间具有统计学上的相似。相关分析表明,个体STAT基因的组织水平之间以及血液水平之间存在显著相关性。然而,组织和血液中每个STAT基因的水平并不相关。目前的研究增强了某些STAT基因在这种免疫相关疾病发展中的作用,并保证了功能分析来阐明其机制。
{"title":"Altered expression of STAT genes in periodontitis.","authors":"Leila Gholami, Abolfazl Movafagh, Elham Badrlou, Naghme Nazer, Mohsen Yari, Ghasem Sadeghi, Sara Mirzajani, Mahdi Shadnoush, Arezou Sayad, Soudeh Ghafouri-Fard","doi":"10.3233/HAB-210444","DOIUrl":"https://doi.org/10.3233/HAB-210444","url":null,"abstract":"<p><p>Signal Transducer and Activator of Transcription (STAT) pathway is functionally located downstream of Janus kinases proteins and can integrate signals from diverse pathways, thus regulating several aspects of immune responses. Although contribution of STAT proteins in the pathogenesis of several inflammatory conditions has been confirmed, their role in the development of periodontitis has been less appraised. Thus, we assessed levels of STAT transcripts in the periodontal tissues and circulation of affected individuals compared with the corresponding controls. Expression of STAT1 was remarkably lower in tissues samples of patients compared with control tissues (Ratio of mean expression (RME) = 0.15, SE = 0.99, P value = 0.01). Expression of STAT3 was lower in total periodontitis tissues compared with total control tissues (RME = 0.20, SE = 0.95, P value = 0.02). Expression of STAT6 was higher in total periodontitis tissues compared with total control tissues (RME = 0.5.38, SE = 0.74, P value < 0.001). Expressions of other STAT genes were statistically similar in tissues obtained from cases and controls. Moreover, blood levels of all STAT genes were statistically similar between patients and controls. Correlation analysis demonstrated significant correlations between tissues levels of individual STAT genes as well as between their blood levels. However, tissue and blood levels of each STAT gene were not correlated. The current investigation potentiates the role of certain STAT genes in the development of this immune-related condition and warrants functional assays to clarify the mechanism.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 3","pages":"209-216"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-210444","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39050903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: COVID-19 is currently the major public health burden in the world, with disease and death in the global community from COVID-19 increasing rapidly from time to time worldwide. However, there has been a lack of well-organized information about the level of risk, effects, prevention and control methods of the disease. Therefore the aim of this study is to identify and review a published level of risk, effects response to potential health emergencies, prevention, and control methods of COVID-19 at a global level.
Method: A systematic review was performed after literatures were identified by searching the following online databases: medRxiv, Google scholar, PubMed, MEDLINE, EMBASE, and the Cochrane Library with supplementary hand searching of conferences. The online databases contain archives of most English biomedical journals. Scientific papers published online by the Center for Disease Control and the World Health Organization were also included for this analysis. The scientific publications from 01 December, 2019 to 13 April 2020 were included. The 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus', and 'Pneumonia' key search terms were used for this review.
{"title":"The level of risk, effects response to potential health emergencies, prevention and control method of COVID-19: A systematic review.","authors":"Addis Adera Gebru, Tadesse Birhanu, Eshetu Wendimu, Agumas Fentahun Ayalew, Selamawit Mulat, Hussen Zakir Abasimel, Ali Kazemi, Bosenu Abera Tadesse, Beniam Adera Gebru, Berhanu Senbeta Deriba, Nigus Shimelis Zeleke, Abebe Gule Girma, Bulgantsetseg Munkhbat, Qamar Kassim Yusuf, Amana Ogeto Luke, Dejene Hailu","doi":"10.3233/HAB-200421","DOIUrl":"https://doi.org/10.3233/HAB-200421","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 is currently the major public health burden in the world, with disease and death in the global community from COVID-19 increasing rapidly from time to time worldwide. However, there has been a lack of well-organized information about the level of risk, effects, prevention and control methods of the disease. Therefore the aim of this study is to identify and review a published level of risk, effects response to potential health emergencies, prevention, and control methods of COVID-19 at a global level.</p><p><strong>Method: </strong>A systematic review was performed after literatures were identified by searching the following online databases: medRxiv, Google scholar, PubMed, MEDLINE, EMBASE, and the Cochrane Library with supplementary hand searching of conferences. The online databases contain archives of most English biomedical journals. Scientific papers published online by the Center for Disease Control and the World Health Organization were also included for this analysis. The scientific publications from 01 December, 2019 to 13 April 2020 were included. The 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus', and 'Pneumonia' key search terms were used for this review.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"149-169"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200421","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38327228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aimed to evaluate the prognostic value of baseline macrophage inflammatory protein (MIP)-1β/IL12p40 ratio for antiviral treatment outcome in HCV genotype 4 patients.
Methods: Sera of 450 treatment-naïve chronic HCV patients and 50 healthy individuals were collected. Liver transaminases, total bilirubin and albumin were biochemically tested, viral RNA was quantified, and circulating MIP-1β and IL-12p40 were estimated using human anti-MIP-1β and IL-12p40 antibodies in Sandwich ELISA.
Results: No difference was observed in the baseline chemokines levels between responders and relapsers, but the later had a significantly higher MIP-1β/IL-12p40 ratio (P< 0.0001). Multivariate regression analysis of baseline characteristics showed that gender, age, viral load, albumin level and chemokine ratios can significantly predict treatment outcome (P= 0.0114, 0.0095, 0.042, 0.0004 and < 0.0001; respectively). Accordingly, a predictive threshold of baseline chemokine ratio was calculated and it showed an AUC of 0.6917 (P= 0.0108; 95% CI: 0.5566 to 0.8268). The calculated threshold for predicting virologic response was 8.245, with positive and negative predictive values of 92.98% and 100%; respectively. The chemokine ratios had significant correlations with liver transaminases in treated groups whether pre or post-treatment.
Conclusion: Baseline MIP-1β/IL-12p40 ratio represents a non-invasive prognostic biomarker that would provide shorter treatment duration and minimizes the emergence of drug-resistant variants in HCV genotype 4-patients.
{"title":"Circulating macrophage inflammatory protein-1β/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patients.","authors":"Heba Shawky, Reem El-Shenawy, Naiera M Helmy","doi":"10.3233/HAB-211504","DOIUrl":"https://doi.org/10.3233/HAB-211504","url":null,"abstract":"<p><p>This study aimed to evaluate the prognostic value of baseline macrophage inflammatory protein (MIP)-1β/IL12p40 ratio for antiviral treatment outcome in HCV genotype 4 patients.</p><p><strong>Methods: </strong>Sera of 450 treatment-naïve chronic HCV patients and 50 healthy individuals were collected. Liver transaminases, total bilirubin and albumin were biochemically tested, viral RNA was quantified, and circulating MIP-1β and IL-12p40 were estimated using human anti-MIP-1β and IL-12p40 antibodies in Sandwich ELISA.</p><p><strong>Results: </strong>No difference was observed in the baseline chemokines levels between responders and relapsers, but the later had a significantly higher MIP-1β/IL-12p40 ratio (P< 0.0001). Multivariate regression analysis of baseline characteristics showed that gender, age, viral load, albumin level and chemokine ratios can significantly predict treatment outcome (P= 0.0114, 0.0095, 0.042, 0.0004 and < 0.0001; respectively). Accordingly, a predictive threshold of baseline chemokine ratio was calculated and it showed an AUC of 0.6917 (P= 0.0108; 95% CI: 0.5566 to 0.8268). The calculated threshold for predicting virologic response was 8.245, with positive and negative predictive values of 92.98% and 100%; respectively. The chemokine ratios had significant correlations with liver transaminases in treated groups whether pre or post-treatment.</p><p><strong>Conclusion: </strong>Baseline MIP-1β/IL-12p40 ratio represents a non-invasive prognostic biomarker that would provide shorter treatment duration and minimizes the emergence of drug-resistant variants in HCV genotype 4-patients.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 4","pages":"263-274"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39407675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: As the extent of the pandemic and its seroprevalence pattern has been less clarified in pediatrics to date, we aimed to conduct this study to investigate the clinical and laboratory characteristics of COVID-19 in Iranian children, with a focus on evaluating the antibody prevalence and its relation with the laboratory tests.
Methods: All children with highly suspected COVID-19 were included. Anti-nucleoprotein SARS-CoV-2 were measured using SARS-CoV-2 immunoglobulin M (IgM) and SARS-CoV-2 IgG ELISA kits. Hypothesis testing was carried out through SPSS to unravel any association between the measurement tools and important clinical and laboratory characteristics.
Results: In this study, 254 patients were evaluated and 117 cases (46%) were male. The nucleic acid detection results for patient 55 were negative, but the IgM and IgG results were positive. Totally, 190 patients were tested for IgM in which only 14 (7.3%) had positive tests. Positive IgG was detected in 51 (20%) out of 254 patients; among them, 30 patients had negative SARS-CoV-2 RT-PCR (59%). Lower level of platelets in IgG positive group in comparison with the IgG negative group was observed (P value: 0.015). Moreover, higher alanine aminotransferase (ALT) was observed in the in IgG positive group (P value: 0.02). In patients with positive IgM, relative hypocalcemia (median of 8.25; IQR: 8.02-8.62) was found which appeared to be significant (P value: 0.02).
Conclusion: This is the first largest study describing the SARS-CoV-2 seropositivity among children in Iran and provides important insight about the COVID-19 infection in children.
{"title":"Detection of SARS-CoV-2 antibodies in pediatric patients: An Iranian referral hospital-based study.","authors":"Setareh Mamishi, Golnaz Ghazizadeh Esslami, Mohsen Mohammadi, Mohammad Reza Abdolsalehi, Reihaneh Hosseinpour Sadeghi, Shima Mahmoudi, Babak Pourakbari","doi":"10.3233/HAB-210448","DOIUrl":"https://doi.org/10.3233/HAB-210448","url":null,"abstract":"<p><strong>Background: </strong>As the extent of the pandemic and its seroprevalence pattern has been less clarified in pediatrics to date, we aimed to conduct this study to investigate the clinical and laboratory characteristics of COVID-19 in Iranian children, with a focus on evaluating the antibody prevalence and its relation with the laboratory tests.</p><p><strong>Methods: </strong>All children with highly suspected COVID-19 were included. Anti-nucleoprotein SARS-CoV-2 were measured using SARS-CoV-2 immunoglobulin M (IgM) and SARS-CoV-2 IgG ELISA kits. Hypothesis testing was carried out through SPSS to unravel any association between the measurement tools and important clinical and laboratory characteristics.</p><p><strong>Results: </strong>In this study, 254 patients were evaluated and 117 cases (46%) were male. The nucleic acid detection results for patient 55 were negative, but the IgM and IgG results were positive. Totally, 190 patients were tested for IgM in which only 14 (7.3%) had positive tests. Positive IgG was detected in 51 (20%) out of 254 patients; among them, 30 patients had negative SARS-CoV-2 RT-PCR (59%). Lower level of platelets in IgG positive group in comparison with the IgG negative group was observed (P value: 0.015). Moreover, higher alanine aminotransferase (ALT) was observed in the in IgG positive group (P value: 0.02). In patients with positive IgM, relative hypocalcemia (median of 8.25; IQR: 8.02-8.62) was found which appeared to be significant (P value: 0.02).</p><p><strong>Conclusion: </strong>This is the first largest study describing the SARS-CoV-2 seropositivity among children in Iran and provides important insight about the COVID-19 infection in children.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 3","pages":"217-223"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-210448","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39251786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nafiseh Faraji, Ahmad Ganji, Neda Heshami, Iraj Salehi, Ahmad Haddadian, Shiva Shojaie, Alireza Komaki
Diets included high-fat (HFD) and high calories intake is correlated with greater risk of obesity and oxidative stress, which lead to increase the risk of related diseases such as cardiovascular and metabolic disease. In the present study, we have examined the hypolipidemic activity of Hypericum Scabrum extract on HFD fed rats. Fifty-four male Wistar rats divided into six groups: 1) control, 2) H. Scabrum extract (100 mg/kg gavage per day), 3) H. Scabrum extract (300 mg/kg), 4) HFD, 5) HFD and H. Scabrum extract (100 mg/kg), 6) HFD and H. Scabrum extract (300 mg/kg). The groups were fed their diet and treatment for 3 months. Biochemical analysis showed elevated lipid serum profile in HFD rats compared to control group. H. Scabrum extract supplementation significantly ameliorated triglyceride, total cholesterol and LDL-cholesterol. H. Scabrum extract supplementation leading to increase HDL-cholesterol in HFD treated groups. This experiment showed that H. Scabrum extract decreased HFD complications and might be beneficial herbal drug for treatment of hyperlipidemia and obesity.
{"title":"Hypolipidemic effects of Hypericum Scabrum extract on the serum lipid profile and obesity in high-fat diet fed rats.","authors":"Nafiseh Faraji, Ahmad Ganji, Neda Heshami, Iraj Salehi, Ahmad Haddadian, Shiva Shojaie, Alireza Komaki","doi":"10.3233/HAB-200430","DOIUrl":"https://doi.org/10.3233/HAB-200430","url":null,"abstract":"<p><p>Diets included high-fat (HFD) and high calories intake is correlated with greater risk of obesity and oxidative stress, which lead to increase the risk of related diseases such as cardiovascular and metabolic disease. In the present study, we have examined the hypolipidemic activity of Hypericum Scabrum extract on HFD fed rats. Fifty-four male Wistar rats divided into six groups: 1) control, 2) H. Scabrum extract (100 mg/kg gavage per day), 3) H. Scabrum extract (300 mg/kg), 4) HFD, 5) HFD and H. Scabrum extract (100 mg/kg), 6) HFD and H. Scabrum extract (300 mg/kg). The groups were fed their diet and treatment for 3 months. Biochemical analysis showed elevated lipid serum profile in HFD rats compared to control group. H. Scabrum extract supplementation significantly ameliorated triglyceride, total cholesterol and LDL-cholesterol. H. Scabrum extract supplementation leading to increase HDL-cholesterol in HFD treated groups. This experiment showed that H. Scabrum extract decreased HFD complications and might be beneficial herbal drug for treatment of hyperlipidemia and obesity.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 1","pages":"55-61"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200430","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38556390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}